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Aims Dialysis patients experience an excess mortality, predominantly of sudden cardiac death (SCD). Accumulating evi-
dence suggests a role of vitamin D for myocardial and overall health. This study investigated the impact of vitamin
D status on cardiovascular outcomes and fatal infections in haemodialysis patients.
Methods
and results
25-hydroxyvitamin D [25(OH)D] was measured in 1108 diabetic haemodialysis patients who participated in the
German Diabetes and Dialysis Study and were followed up for a median of 4 years. By Cox regression analyses,
we determined hazard ratios (HR) for pre-speciﬁed, adjudicated endpoints according to baseline 25(OH)D levels:
SCD (n ¼ 146), myocardial infarction (MI, n ¼ 174), stroke (n ¼ 89), cardiovascular events (CVE, n ¼ 414), death
due to heart failure (n ¼ 37), fatal infection (n ¼ 111), and all-cause mortality (n ¼ 545). Patients had a mean age
of 66+8 years (54% male) and median 25(OH)D of 39 nmol/L (interquartile range: 28–55). Patients with severe
vitamin D deﬁciency [25(OH)D of≤ 25 nmol/L] had a 3-fold higher risk of SCD compared with those with sufﬁcient
25(OH)D levels .75 nmol/L [HR: 2.99, 95% conﬁdence interval (CI): 1.39–6.40]. Furthermore, CVE and all-cause
mortality were strongly increased (HR: 1.78, 95% CI: 1.18–2.69, and HR: 1.74, 95% CI: 1.22–2.47, respectively), all
persisting in multivariate models. There were borderline non-signiﬁcant associations with stroke and fatal infection
while MI and deaths due to heart failure were not meaningfully affected.
Conclusion Severe vitamin D deﬁciency was strongly associated with SCD, CVE, and mortality, and there were borderline associ-
ations with stroke and fatal infection. Whether vitamin D supplementation decreases adverse outcomes requires
further evaluation.
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VitaminD deﬁciencyisobservedinthevastmajorityofhaemodialysis
patients,andthereisaccumulatingevidencethatvitaminD,beyondits
effects on bone and mineral metabolism, is also crucial for cardiovas-
cular health and protection against infectious diseases.
1–9 In general,
vitamin D from either ultraviolet B-induced synthesis in the skin or
from nutritional intake is hydroxylated to 25-hydroxyvitamin D
[25(OH)D] in the liver. 25(OH)D circulates in up to 1000-fold
higher concentrations than the most potent vitamin D metabolite
1,25-dihydroxyvitamin D [1,25(OH)2D, calcitriol].
8,9 The renal pro-
ductionof1,25(OH)2Distightlycontrolledbyhomoeostaticmechan-
isms but becomes signiﬁcantly dependent on substrate availability
when circulating 25(OH)D are low.
8 In addition, various extrarenal
tissues including the myocardium and vasculature have been shown
to express 1a-hydroxylase and are thus capable of producing large
amounts of 1,25(OH)2D.
8,9 Of note, locally produced 1,25(OH)2D,
the synthesis of which is dependent on circulating 25(OH)D levels,
exerts its effects predominantly in an autocrine and paracrine
manner thereby regulating approximately 3% of the human
genome.
8–10
In patients with chronic kidney disease (CKD), limited sunlight
exposure and reduced capacity of the skin to synthesize vitamin D
as well as loss of vitamin D-binding protein in the urine are mainly
responsible for the high prevalence of depressed 25(OH)D levels,
which are used to assess vitamin D status.
1–9,11 Given that the
kidney is the main source for circulating 1,25(OH)2D, which is
crucial for calcium and phosphorus as well as parathyroid hormone
(PTH)homeostasis,1,25(OH)2Dand itsanaloguesareroutinelysup-
plementedinmanyend-stageCKDpatients,andthistherapyisassoci-
ated with improved survival.
10 Besides the use of this therapy with
active vitamin D, little attention has been paid in the past to
25(OH)D levels, which can be raised by supplementation with the
precursor vitamin D. Recent studies have, however, shown that in
CKDlow25(OH)Dlevelsareasigniﬁcantriskfactorforcardiovascu-
lar diseases (CVDs) and mortality.
1–7 In a nested case–control study
among 1000 incident haemodialysis patients, there was a signiﬁcantly
increased 90-day mortality in the group with the lowest 25(OH)D
levels.
4 However, data on long-term mortalityand speciﬁc cardiovas-
cular events (CVE), such as sudden cardiac death (SCD) or stroke,
being signiﬁcantly associated with vitamin D deﬁciency in patients
undergoing coronary angiography,
12,13 are lacking for haemodialysis
patients. In view of the particularly high incidence of SCD in dialysis
patients, accounting for one-quarter of all deaths, such data are
needed to gain a better understanding of the diagnostic and probably
therapeutic implications of vitamin D in these patients. Hence, we
investigated the effect of 25(OH)D levels on SCD in relation to
othercardiac,vascular,andinfection-relatedoutcomesinalargewell-
characterized cohort of haemodialysis patients.
14
Methods
Study design and participants
The German Diabetes and Dialysis Study (4D study) methodology has
previouslybeenreportedindetail.
14Brieﬂy,the4Dstudywasaprospec-
tiverandomizedcontrolledtrial(RCT),including1255patientswithtype
2 diabetes mellitus, aged 18–80 years, and on haemodialysis for ,2
years. Between March 1998 and October 2002, patients were recruited
in 178 dialysis centres in Germany. After a period of 4 weeks, patients
were randomly assigned to double-blinded treatment with either
20 mg of atorvastatin (n ¼ 619) or placebo (n ¼ 636) once daily. Study
visits took place three times before randomization (Visits 1–3), at ran-
domization (Visit 4), and at 4 weeks (Visit 5), and every 6 months
(Visit 6) after randomization until the date of death, censoring, or end
of the study in March 2004. The primary endpoint of the 4D study was
deﬁned as a composite of death from cardiac causes, fatal or non-fatal
stroke, and non-fatal myocardial infarction (MI), whichever occurred
ﬁrst (composite cardiovascular endpoint; CVE). Death from cardiac
causes comprised SCD, fatal MI, death due to congestive heart failure
(CHF), death due to coronary heart disease during or within 28 days
after an intervention, and all other deaths ascribed to coronary heart
disease.Suddencardiacdeathwasconsideredas:deathveriﬁedbyterm-
inal rhythm disorders in an electrocardiogram; by witnesses observed
death within 1 h after the onset of cardiac symptoms; conﬁrmed by
autopsy; unexpected death, presumably or possibly of cardiac origin
and in the absence of a potassium level ≥7.5 mmol/L before the start
ofthethreemostrecentsessionsofhaemodialysis.Myocardialinfarction
wasdiagnosedwhentwoofthefollowingthreecriteriaweremet:typical
symptoms, elevated levels of cardiac enzymes (i.e. a level of creatine
kinase MB above 5% of the total level of creatine kinase, a level of
lacticdehydrogenase1.5timestheupperlimitofnormal,oraleveloftro-
ponin T .2 ng/mL), or diagnostic changes on the electrocardiogram.
German Diabetes and Dialysis Study endpoints were centrally adjudi-
cated by three members of the endpoint committee blinded to study
treatment and according to pre-deﬁned criteria.
In the present analysis, SCD, MI (fatal and non-fatal), stroke (fatal
and non-fatal), the primary endpoint (CVE), death due to CHF,
death due to infection, and all-cause mortality were all chosen to be
separate outcome measures. The study complies with the Declaration
of Helsinki, was approved by the medical Ethics Committee, and all
patients gave their written informed consent before inclusion.
Data collection
Information on age, gender, and smoking status was obtained through
patient interviews. Smoking status was classiﬁed as never, former, or
current. Comorbidities, including the presence of coronary artery
disease (CAD) and CHF, as well as the duration of diabetes mellitus
anddialysistreatmentwerereportedbythepatients’nephrologists.Cor-
onary artery disease was deﬁned by the history of MI, coronary artery
bypass grafting surgery, percutaneous coronary intervention, and the
presence of coronary heart disease, as documented by coronary angio-
graphy. Left ventricular hypertrophy (LVH) was based on ECG criteria.
Blood pressure was measured in sitting position. Body mass index
(BMI) was calculated as weight (kg) divided by height (m) squared.
Levels of 25(OH)D were measured in serum samples taken at baseline
at study Visit 3 (1 week before randomization) and stored without
repeated freezethawcyclesat 2808C until measurement inNovember
2009. Determinations in serum were performed by means of a chemilu-
minescence assay (IDS, iSYS 25(OH)D; Immunodiagnostic systems Ltd,
Boldon,UK)onanIDS-iSYSmulti-disciplineautomatedanalyser.Within-
day coefﬁcients of variation (CV) were 5.5–12.1% and inter-day CV
were 8.9–16.9%, respectively. All blood samples were taken before
the start of dialysis sessions and administration of drugs.
Statistical analysis
Continuous variables were expressed as mean with standard deviation
or median with interquartile range as appropriate, and categorical vari-
ables were expressed as percentages.
C. Drechsler et al. 2254The study population was divided into four groups according to
their 25(OH)D status at baseline. In line with widely used cut-off
values, patients were grouped into severely vitamin D deﬁcient
(≤25 nmol/L), moderately vitamin D deﬁcient (.25 and ≤50 nmol/L),
vitamin D insufﬁcient (.50 and ≤75 nmol/L), and vitamin D sufﬁcient
(.75 nmol/L, to convert nanomolar to nanogram per millilitre divide
by 2.496).
4,8,12 For comparisons across baseline vitamin D groups, we
used ANOVA and x
2 test, as appropriate. In our prospective analyses,
we assessed the association of baseline 25(OH)D with SCD, both as
continuous and as categorical variable. For the latter, the patients with
sufﬁcient 25(OH)D levels were used as the reference group. Absolute
(incidence) rates were calculated, and the relative risks derived from
Cox regression analyses, i.e. hazard ratios (HR) and corresponding
95% conﬁdence intervals (CI). The Cox regression analyses were
adjusted for the confounders age, sex, atorvastatin treatment, use of
angiotensin-converting enzyme inhibitors, beta-blockers, and diuretics,
CAD, CHF, systolic blood pressure, smoking status, duration of dialy-
sis, ultraﬁltration volume, BMI, levels of low-density lipoprotein
(LDL)-cholesterol, high-density lipoprotein (HDL)-cholesterol, C-
reactive protein, and glycohaemoglobin A1c. To account for the sea-
sonal variation of 25(OH)D, we furthermore adjusted our analyses for
the season of blood draw. We, therefore, used a binary variable
reﬂecting the months October to March and April to September.
Second, to explore the possible pathways, we performed additional
analyses with inclusion of potential intermediate conditions including
levels of calcium, PTH, and phosphate. The use of active vitamin D
treatment was, furthermore, considered in additional multivariate ana-
lyses. Third, we investigated 25(OH)D and the risk of other adverse
cardiac and vascular outcomes including MI, stroke, the combined
primary endpoint, and death due to CHF. Furthermore, we evaluated
the association of 25(OH)D levels with all-cause mortality and fatal
infections. In addition, we used an alternative approach to account
for the seasonal ﬂuctuation of 25(OH)D and calculated z-values of
logarithmically transformed 25(OH)D levels based on their means
and standard deviation values within each month of blood sampling
(formula for z-values: X-mean/standard deviation). Finally, we tested
for interactions of statin use (yes/no), active vitamin D treatment
(yes/no), prior CVD (yes/no), and event rates in our prospective ana-
lyses by adding product terms to our Cox proportional hazards
models.
All P-values are reported two-sided, and a P-value ,0.05 was con-
sidered statistically signiﬁcant. Analyses were performed using SPSS
version 16.0.
Results
Patient characteristics
Between March 1998 and October 2002, a total of 1255 patients
were included into the 4D study, of whom 1108 had a measure-
ment of 25(OH)D at baseline. The mean follow-up period was
3.96 years (median 4.0 years) on atorvastatin and 3.91 years
(median 4.08 years) on placebo. During follow-up, 414 of the
1108 patients reached the primary endpoint of CVE. In our
primary analyses, there was no signiﬁcant effect of atorvastatin
treatment on CVE.
14 A total of 545 patients died, of whom 146
patients died of SCD. Furthermore, 37 patients died due to
CHF, and 111 patients died due to infection. A total of 174 patients
experienced an MI (fatal or non-fatal) and 89 patients experienced
a stroke (fatal or non-fatal).
In the study population (n ¼ 1108), the mean (standard devi-
ation) age was 66 (8) years and 54% of the patients were male.
In general, the median (interquartile) level of 25(OH)D at baseline
was 39 nmol/L (28–55). As expected, we observed a seasonal vari-
ation of 25(OH)D in our patients, with the lowest median concen-
trations of 31 nmol/L in February and the highest median
concentrations of 50 nmol/L in August. The patient characteristics
are shown in Table 1. Patients with severe vitamin D deﬁciency
were more likely to be female and had higher levels of glycohae-
moglobin A1c. Furthermore, the burden of LVH was higher, as
were the levels of LDL-cholesterol and N-terminal-pro-B-type
natriuretic peptide in patients with severe vitamin D deﬁciency
compared with patients with sufﬁcient 25(OH)D levels.
Vitamin D status and risk of sudden
cardiac death
Vitamin D status at baseline was strongly associated with the risk of
SCD (Figure 1A). By Cox regression analyses, the unadjusted
hazard to experience SCD was 3-fold higher in patients with
severe vitamin D deﬁciency as compared with those with sufﬁcient
25(OH)D levels (HR: 2.99, 95% CI: 1.39–6.40, Table 2). This
association was virtually unchanged after controlling for potential
confounders and seasonal variation of 25(OH)D (HR: 2.95, 95%
CI: 1.35–6.46). Additional adjustment for markers of mineral
metabolism including PTH, calcium, and phosphate also did not
materially change the results (HR: 3.00, 95% CI: 1.36–6.60),
which persisted even after further adjustment for the use of
active vitamin D treatment (HR: 3.04, 95% CI: 1.38–6.70). When
25(OH)D was analysed as a continuous variable, the hazard to
die suddenly increased by 59% per unit decrease in 25(OH)D
levels (Table 3). This association persisted in multivariate analyses.
To strengthen our results, we performed additional analyses using
z-values as an alternative approach to account for the seasonal
variation of 25(OH)D. The results were similar, conﬁrming a
strong association of low 25(OH)D levels with the risk of SCD
(data not shown).
Vitamin D status and risk of myocardial
infarction, stroke, death due to heart
failure, and combined cardiovascular
events
There was a trend for higher risks of stroke with lower 25(OH)D
levels (Figure 1B). Per unit decrease in 25(OH)D, the risk of stroke
increased by 30% after adjustment for confounders. In categorical
analyses, patients with severe vitamin D deﬁciency had a 2.8-fold
increased risk of stroke compared with those with normal levels
(adjusted HR: 2.83, 95% CI: 0.82–9.80). In contrast, no association
of vitamin D status with MI was found. Both in continuous
(adjusted HR: 1.04, 95% CI: 0.76–1.44) and in categorical analyses,
the risk of MI did not increase at lower levels of 25(OH)D
(Tables 2 and 3). When non-fatal and fatal MI were analysed separ-
ately, the results were similar showing no relation to vitamin D
status. The number of deaths due to CHF was small in the
present study (n ¼ 37). These deaths similarly were not meaning-
fully affected by vitamin D status.
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Table 1 Baseline patient characteristics, presented per vitamin D category; study population (n 5 1108)
Characteristic Vitamin D category [25(OH)D levels in nmol/L] P-value
≤25 (n 5 177) >25 and ≤50 (n 5 607) >50 and ≤75 (n 5 210) >75 (n 5 114)
Age (years) 66 (8) 66 (8) 65 (8) 65 (8) 0.395
Gender (%, (men) 49.2 49.1 66.2 67.5 ,0.001
25(OH)D (nmol/L) 20 (17–23) 35 (30–42) 61 (56–67) 94 (83–104) ,0.001
Atorvastatin treatment (%) 52.0 49.8 49.0 49.1 0.940
Use of active vitamin D (%) 22.6 16.8 21.0 14.9 0.175
Systolic BP (mmHg) 146 (22) 146 (23) 144 (20) 147 (22) 0.772
Diastolic BP (mmHg) 76 (11) 76 (11) 76 (11) 77 (10) 0.495
BMI (kg/m
2) 27.4 (5.3) 27.7 (4.7) 27.5 (4.6) 27.0 (4.1) 0.505
Duration of diabetes (years) 19.9 (13.5–25.7) 18.0 (11.4–23.8) 16.3 (10.0–23.2) 18.3 (9.9–22.5) 0.003
Time on dialysis (months) 5.7 (3.2–12.1) 6.0 (2.9–11.3) 5.8 (3.1–11.7) 7.3 (3.9–12.1) 0.336
Ultraﬁltration volume (kg) 2.0 (1.2–3.0) 2.0 (1.1–3.0) 2.0 (2.0–3.0) 2.0 (1.0–3.0) 0.420
Smoker/ex-smoker (%) 42.9 37.8 43.3 44.7 0.247
History of
CAD (%) 28.8 27.3 32.4 36.8 0.159
CHF (%) 37.9 35.9 31.0 40.4 0.320
Presence of LVH (%) 14.1 11.7 11.4 12.4 0.832
NYHA class I (%) 66.1 72.0 76.1 61.4 0.039
NYHA class II (%) 27.7 23.4 17.6 31.6
NYHA class III (%) 6.2 4.6 5.7 7.0
NYHA class IV (%) 0.0 0.0 0.5 0.0
Beta-blockers (%) 26.0 35.3 44.3 48.2 ,0.001
ACE inhibitors (%) 41.8 45.8 52.4 57.0 0.027
Diuretics (%) 80.8 81.2 77.6 75.4 0.418
Laboratory parameters
LDL-cholesterol (mg/dL) 128 (111–145) 122 (104–145) 121 (103–141) 118 (101–142) 0.023
HDL-cholesterol (mg/dL) 35 (28–44) 33 (27–42) 33 (26–42) 36 (30–44) 0.083
Triglycerides (mg/dL) 244 (165–322) 225 (148–325) 222 (160–328) 185 (135–302) 0.110
Haemoglobin (g/dL) 11.0 (1.4) 10.9 (1.4) 11.0 (1.3) 10.9 (1.2) 0.533
Albumin (g/dL) 3.8 (0.3) 3.8 (0.3) 3.8 (0.3) 3.9 (0.3) 0.063
C-reactive protein (mg/L) 4.9 (2.5–10.9) 5.2 (2.5–13.3) 5.3 (2.4–14.2) 4.5 (2.1–10.3) 0.489
HbA1c (%) 6.8 (1.3) 6.8 (1.3) 6.6 (1.1) 6.5 (1.2) 0.051
Calcium (mmol/L) 2.3 (0.2) 2.3 (0.2) 2.3 (0.2) 2.3 (0.2) 0.161
Phosphate (mmol/L) 6.2 (1.5) 6.0 (1.6) 6.1 (1.6) 5.7 (1.6) 0.060
NT-pro-BNP (pg/mL) 3690 (1479–8080) 3523 (1524–10 396) 3036 (1171–7659) 2608 (1087–7026) 0.010
Values are presented as means (SD) or median (interquartile range) or %.
HbA1c, haemoglobin A1c; BP, blood pressure; BMI, body mass index; CAD, coronary artery disease; CHF, congestive heart failure; LVH, left ventricular hypertrophy; LDL, low-density lipoprotein; HDL, high-density lipoprotein; NT-pro-BNP,
N-terminal-pro-B-type natriuretic peptide.
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6Finally, the primary endpoint of combined CVE was markedly
increased with lower levels of 25(OH)D (Table 2 and Figure 1C).
Patients with severe vitamin D deﬁciency had an adjusted 80%
higher risk of experiencing a CVE as compared with patients
with sufﬁcient vitamin D status (Table 3).
Vitamin D status and risk of death due to
infection and all-cause mortality
Deaths due to infection were almost 2-fold increased in patients
suffering from severe vitamin D deﬁciency (adjusted HR: 1.92,
95% CI: 0.82–4.51). Per unit decrease in log transformed
25(OH)D, the rate of fatal infections rose by 46% (adjusted HR:
1.46, 95% CI: 0.96–2.23). Furthermore, deaths due to all causes
increased signiﬁcantly by 39% per unit decrease in log 25(OH)D.
Patients with levels ,25 nmol/L had an adjusted 79% higher risk
of death as compared with patients with sufﬁcient 25(OH)D
levels (Tables 2 and 3).
There were no signiﬁcant interactions of statin use, active
vitamin D treatment as well as prior CVD in our prospective ana-
lyses indicating that the association of 25(OH)D levels with event
rates is not different in patients with and without statin or active
vitamin D treatment as well as prior CVD.
Linearity assumptions for all Cox regression analyses were eval-
uated by log-minus-log survival plots and partial (Scho ¨nfeld)
residuals vs. survival time plots and found valid.
Discussion
We have shown that vitamin D deﬁciency is an independent risk
factor for SCD, CVE, and all-cause mortality in diabetic haemodia-
lysis patients. These associations were independent of common
known risk factors. There were also borderline non-signiﬁcant
associations of severe vitamin D deﬁciency with increased risk of
stroke and fatal infections.
Our study is the ﬁrst to highlight the role of vitamin D deﬁciency
as a risk factor of adverse long-term outcomes in diabetic haemo-
dialysis patients. Strengths of our study are the large sample size,
the well-characterized cohort of diabetic haemodialysis patients,
and the detailed long-term follow-up. Our data are in line with
observations in other cohorts of CKD patients,
2–7 inpatients
referred for coronary angiography,
12,13 as well as in population-
based cohorts.
15–18 These latter studies showed an increased
risk of mortality and/or CVE in individuals with low 25(OH)D
levels.
2–7,12,13,15–18 Previous observations on speciﬁcally strong
associations of vitamin D deﬁciency with MI and heart failure
could, however, not be clearly conﬁrmed in the 4D study.
12,16
Given that most haemodialysis patients are vitamin D deﬁcient,
we believe that our ﬁndings might have signiﬁcant clinical impli-
cations when considering that natural vitamin D supplementation
is considered a relatively safe, easy, and cheap therapy.
19 We are
aware of a history of promising data on risk factors of mortality
in haemodialysis patients leading to the initiation of RCTs, which
failed to show signiﬁcant effects of targeted treatments.
20
Without claiming causality for our ﬁndings, we want to stress
that vitamin D exerts various effects that might, in a causal
manner, underlie harmful consequences of vitamin D deﬁciency.
10
Figure 1 Kaplan–Meier curves for the time to (A) sudden
cardiac death, (B) stroke, (C) combined cardiovascular events in
subgroups of patients according to 25-hydroxyvitamin D levels at
baseline [severely vitamin D deﬁcient (≤25 nmol/L), moderately
vitamin D deﬁcient (.25 and ≤50 nmol/L), vitamin D insufﬁcient
(.50 and ≤75 nmol/L), and vitamin D sufﬁcient (.75 nmol/L)].
Vitamin D and sudden cardiac death in dialysis 2257First, we want to point out that classic effects of vitamin D
related to calcium and phosphorus homoeostasis as well as PTH
regulation might of course play an important role for cardiovascu-
lar risk in CKD.
21 Reduced vitamin D metabolites lead to hypocal-
caemia and secondary hyperparathyroidism, which is associated
with increased mortality risk.
22–24 In this context, previous
studies indicate that natural vitamin D or 25(OH)D supplemen-
tation might have beneﬁcial effects on mineral metabolism includ-
ing reductions in PTH levels.
22,25 Results on this latter topic are,
however, inconsistent and further studies are required.
22,25 Inter-
estingly, our prospective results did not materially change even
after adjustments for various parameters of mineral metabolism
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Table 2 Absolute incidence rates and hazard ratios with 95% conﬁdence intervals (HR, 95% CI) for sudden cardiac
death, stroke, myocardial infarction, and death due to heart failure according to levels of 25-hydroxyitamin D at baseline
(n 5 1108)
Outcome Vitamin D (nmol/L)
≤25 (n 5 177) >25 and ≤50 (n 5 607) >50 and ≤75 (n 5 210) >75 (n 5 114)
Sudden cardiac death
Incidence rate/100 persons-years py 7.4 4.5 3.7 2.5
Crude HR (95% CI) 2.99 (1.39–6.40) 1.83 (0.89–3.79) 1.49 (0.66–3.35) 1
Adjusted
a HR (95% CI) 2.95 (1.35–6.46) 1.71 (0.82–3.60) 1.54 (0.68–3.50) 1
Adjusted
b HR (95% CI) 3.00 (1.36–6.60) 1.74 (0.83–3.65) 1.54 (0.68–3.51) 1
Stroke
Incidence rate/100 py 3.8 2.6 3.8 1.2
Crude HR (95% CI) 2.97 (1.01–8.75) 2.08 (0.75–5.78) 3.11 (1.07–9.03) 1
Adjusted
a HR (95% CI) 2.83 (0.82–9.80) 1.92 (0.58–6.27) 3.53 (1.04–11.92) 1
Adjusted
b HR (95% CI) 2.58 (0.74–8.98) 1.79 (0.55–5.90) 3.26 (0.96–11.07) 1
Myocardial infarction
Incidence rate/100py persons-years 6.7 5.2 7.1 5.2
Crude HR (95% CI) 1.29 (0.71–2.34) 1.00 (0.59–1.71) 1.37 (0.76–2.45) 1
Adjusted
a HR (95% CI) 1.40 (0.76–2.59) 1.07 (0.62–1.84) 1.44 (0.80–2.60) 1
Adjusted
b HR (95% CI) 1.27 (0.68–2.36) 1.01 (0.58–1.74) 1.34 (0.74–2.42) 1
Death due to heart failure
Incidence rate/100py persons-years 1.6 1.0 1.2 1.2
Crude HR (95% CI) 1.27 (0.38–4.23) 0.85 (0.29–2.50) 0.95 (0.28–3.25) 1
Adjusted
a HR (95% CI) 1.26 (0.36–4.43) 0.72 (0.23–2.22) 0.89 (0.25–3.12) 1
Adjusted
b HR (95% CI) 0.96 (0.27–3.41) 0.61 (0.20–1.90) 0.67 (0.19–2.44) 1
Cardiovascular events
Incidence rate/100py persons-years 18.2 13.0 16.1 10.2
Crude HR (95% CI) 1.78 (1.18–2.69) 1.28 (0.88–1.87) 1.59 (1.05–2.40) 1
Adjusted
a HR (95% CI) 1.75 (1.14–2.69) 1.24 (0.84–1.83) 1.65 (1.08–2.51) 1
Adjusted
b HR (95% CI) 1.59 (1.03–2.45) 1.18 (0.80–1.75) 1.53 (1.01–2.34) 1
Death due to infection
Incidence rate/100py
persons-years
4.3 3.6 3.5 2.2
Crude HR (95% CI) 1.92 (0.82–4.51) 1.67 (0.76–3.65) 1.66 (0.71–3.91) 1
Adjusted
a HR (95% CI) 1.85 (0.77–4.43) 1.51 (0.68–3.36) 1.61 (0.68–3.84) 1
Adjusted
b HR (95% CI) 1.55 (0.64–3.73) 1.35 (0.61–3.02) 1.34 (0.56–3.23) 1
All-cause mortality
Incidence rate/100py persons-years 22.9 17.1 15.1 13.0
Crude HR (95% CI) 1.74 (1.22–2.47) 1.32 (0.96–1.83) 1.17 (0.81–1.69) 1
Adjusted
a HR (95% CI) 1.79 (1.24–2.59) 1.26 (0.90–1.76) 1.25 (0.86–1.81) 1
Adjusted
b HR (95% CI) 1.65 (1.14–2.38) 1.20 (0.86–1.68) 1.16 (0.80–1.70) 1
aModel 1: adjusted forage, sex,atorvastatintreatment, season, coronaryartery disease, congestive heart failure,systolic blood pressure, smoking, durationof dialysis, ultraﬁltration
volume, body mass index, levels of LDL, HDL cholesterol, C-reactive protein, HbA1c, use of beta-blockers, ACE inhibitors, and diuretics.
bModel 2: additionally adjusted for levels of parathyroid hormone, calcium, and phosphate.
C. Drechsler et al. 2258suggesting that other mechanisms might have mainly driven the
association of low 25(OH)D and adverse outcomes in the 4D
study. Associations of vitamin D deﬁciency with cardiovascular
risk factors including type 2 diabetes mellitus,
26 arterial hyperten-
sion,
27 malnutrition, and inﬂammation may hypothetically explain
the increased mortality risk in patients with low 25(OH)D levels.
Adjustments for these latter risk factors had, however, only little
impact on our prospective analyses. Hence, other mechanisms
may be relevant. Data from the Multi-Ethnic Study of Athero-
sclerosis suggest that vitamin D deﬁciency is prospectively associ-
ated with increased risk of coronary artery calciﬁcation.
28 This
relationship seemed to be stronger for patients with lower esti-
mated glomerular ﬁltration rate, and there was no signiﬁcant
association of 1,25(OH)2D and coronary artery calciﬁcation.
28
This latter result does not necessarily argue against important vas-
cular protective actions of 1,25(OH)2D because circulating levels
of 1,25(OH)2D are not necessarily correlated with its tissue
levels. Previous study results suggest direct anti-atherosclerotic
effects on endothelial and vascular smooth muscle cells as well
as on macrophages whose foam cell formation was inhibited by
1,25(OH)2D.
29,30 The strong association of vitamin D deﬁciency
with SCD but not with MI might, however, suggest that
atherosclerosis related to vitamin D deﬁciency might not be the
main pathophysiological link for our ﬁndings. Direct vitamin D
effects on the myocardium, which expresses the vitamin D recep-
tor (VDR) as well as 1a-hydroxylase,
31,32 may, therefore, be of
importance. Experimental animal studies revealed myocardial
hypertrophy and dysfunction with a hypercontractile state in
both conditions of vitamin D deﬁciency as well as in VDR knockout
models,
10,33,34 even if VDR knockout was exclusively performed in
cardiomyocytes.
35 Clinical studies conﬁrmed the associations of
vitamin D deﬁciency with CHF and in particular with diastolic dys-
function but our results regarding heart failure deaths, which are
limited by relatively low numbers of events, do not support an
important role of vitamin D in this context.
31,36,37 Furthermore,
altered myocardial calcium ﬂux and increased risk of SCD
related to a poor vitamin D status suggest a link to cardiac arrhyth-
mias.
12,31,38 This notion is in line with observations in haemodialysis
patients showing that calcitriol reduced a prolonged QT interval,
which is a risk factor for SCD, the single largest cause of death
in dialysis patients.
39,40 Apart from this, detrimental consequences
of vitamin D deﬁciency might also be mediated by an increased risk
of infections, which is supported by our data showing a borderline
non-signiﬁcant association of vitamin D deﬁciency with fatal infec-
tions.
41 In line with previous data, we also found a non-signiﬁcant
association of low 25(OH)D levels with increased risk of strokes.
13
With reference to strokes, vitamin D might not only be useful for
the prevention but also for the treatment when considering its
neuromuscular and osteoprotective effects.
8–10
Our data should be viewed in light of a meta-analysis, which
showed signiﬁcantly improved survival of natural vitamin D sup-
plementation in individuals without end-stage renal failure.
42 We
are aware that ﬁndings from RCTs among patients free of
advanced CKD cannot be uncritically extrapolated to haemodialy-
sis patients.
20,22 We also want to underline that physicians,
impressed by previous data in favour of multiple health beneﬁts
of natural vitamin D and by the magnitude of the present observed
associations should not abstain from future RCTs, which are
urgently needed. Unless these trial results are published, our
vitamin D prescription among haemodialysis patients should be
guided by considerations that weight the probable beneﬁt vs. the
probable risks and costs of this therapy. Supplementation of
natural vitamin D to reach proposed optimal 25(OH)D levels
of 75–150 nmol/L is considered safe (intoxication starts at
.500 nmol/L),
43 and it should be kept in mind that sunbathing
can produce up to 20 000 IU vitamin D per day.
8,9,19 This latter
dose is much higher than required to reach 25(OH)D target
levels by using the rule of thumb that 1000 IU vitamin D can
increase 25(OH)D levels by  25 nmol/L in patients without
severe CKD.
8,9,19
It should, however, also be pointed out that reversed causation
might be mainly responsible for our prospective results. Hence,
we cannot rule out that vitamin D deﬁciency is simply a conse-
quence of a poor health status and not the cause of an
adverse health outcome. In this context, it should be mentioned
that our data are limited due to the observational nature of our
study, which precludes any conclusion regarding cause and effect
relationships of our results. Despite the extensive adjustments,
we cannot exclude residual confounding. A further limitation of
...............................................
................................................................................
Table 3 Risk of cardiovascular events, sudden cardiac
death, stroke, myocardial infarction, death due to heart
failure, death due to infection, and all-cause mortality
per unit decrease in 25-hydroxyvitamin D (continuous
variable, log transformed); study population (n 5 1108)
Outcome Hazard ratio (HR) and 95% CI
Crude Adjusted
a Adjusted
b
Sudden cardiac death 1.59 1.55 1.58
(1.14–2.23) (1.08–2.23) (1.09–2.27)
P ¼ 0.007 P ¼ 0.017 P ¼ 0.015
Stroke 1.45 1.30 1.27
(0.94–2.23) (0.81–2.07) (0.79–2.03)
P ¼ 0.09 P ¼ 0.27 P ¼ 0.32
Myocardial infarction 0.99 1.04 1.02
(0.73–1.35) (0.76–1.44) (0.74–1.40)
P ¼ 0.96 P ¼ 0.79 P ¼ 0.92
Death due to heart failure 0.96 0.97 0.93
(0.50–1.85) (0.47–2.00) (0.45–1.92)
P ¼ 0.90 P ¼ 0.94 P ¼ 0.84
Cardiovascular events 1.18 1.15 1.12
(0.96–1.43) (0.93–1.42) (0.91–1.38)
P ¼ 0.11 P ¼ 0.19 P ¼ 0.29
Death due to infection 1.44 1.46 1.42
(0.98–2.12) (0.96–2.23) (0.93–2.15)
P ¼ 0.06 P ¼ 0.07 P ¼ 0.10
All-cause mortality 1.38 1.39 1.36
(1.16–1.64) (1.15–1.68) (1.13–1.64)
P , 0.001 P ¼ 0.001 P ¼ 0.001
aModel 1: adjusted for age, sex, atorvastatin treatment, season, coronary artery
disease, congestive heart failure, systolic blood pressure, smoking, duration of
dialysis, ultraﬁltration volume, body mass index, levels of LDL-, HDL-cholesterol,
C-reactive protein, HbA1c, use of beta-blockers, ACE inhibitors, and diuretics.
bModel 2: additional adjustments for PTH, calcium, and phosphate.
Vitamin D and sudden cardiac death in dialysis 2259our work is that due to lack of data we were not able to study
interactions and confounding by levels of 1,25(OH)2D or ﬁbro-
blast growth factor-23, which suppresses 1,25(OH)2D syn-
thesis.
44 Associations of 25(OH)D and outcome measures
were, however, independent of parameters of mineral metab-
olism and the use of active vitamin D treatment. Another draw-
back of our work is missing data on left ventricular ejection
fraction and severity of CAD.
In conclusion, we observed that low 25(OH)D levels are associ-
ated with increased risks of SCD, CVE, and mortality, and there
was, furthermore, a borderline non-signiﬁcant association of
vitamin D deﬁciency with increased risk of strokes and fatal infec-
tions. The magnitude of the observed associations, as well as pre-
vious data in favour of multiple health beneﬁts of natural vitamin D,
point to the urgent need for an RCT. Such study can clarify
whether the relatively easy, safe, and cheap supplementation
therapy with vitamin D can decrease adverse outcomes, in particu-
lar SCD, in haemodialysis patients.
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Acute myocardial infarction secondary to direct myocardial inﬁltration by
a malignant neoplasia
David Vivas*, Borja Ruiz-Mateos, and Eduardo Franco
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A 24-year-old male, with a previous history of osteosar-
coma with cerebral and pulmonary metastasis, presented
to the emergency room with severe chest pain, dyspnoea,
and diaphoresis. Physical examination revealed an apical S4
gallop, abolition of left breath sounds, and right hemipare-
sia. On electrocardiogram, persistent lateral ST-segment
elevation was noted (Panel A). Echocardiogram showed
lateral akinesis with global left ventricular ejection fraction
preserved, severe pericardial effusion probably related to
the malignant neoplasia, and inﬁltration of mediastinum by
the pulmonary metastasis (arrows, Panel B). He was
referred for urgent coronary angiography, which revealed
no signiﬁcant stenosis (Panels C and D). Interestingly, ventri-
culography showed a great distance between epicardic cor-
onary arteries and left ventricular cavity (Panel E). Magnetic
resonance imaging was performed and conﬁrmed the direct
inﬁltration of the neoplasia in the pericardium and myocar-
dium (arrows, Panel F). The patient was treated with anti-
ischaemic and opiate analgesic drugs and died a few days
later by respiratory failure.
Malignant cardiac neoplasias are an extremely unusual
cause of acute myocardial infarction, usually a consequence
of an external compression of large coronary arteries by
inﬁltrative processes or coronary tumour embolisms. To
the best of our knowledge, this is the ﬁrst report of an
acute myocardial infarction caused by direct myocardial
neoplasic inﬁltration.
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